Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.33 |
| ▸ | ITGAV | P06756 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | CCR5 | P51681 | 1/20 | 0.33 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.33 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8123690 | 0.83 | LTA4H (0.52) | GAALTA4HCHRM4KMT2A | |
| SCHEMBL4286523 | 0.78 | PKM (0.54) | HDAC6HDAC1HDAC8PKMGAA | |
| SCHEMBL4293744 | 0.77 | LTA4H (0.38) | HDAC6HDAC1HDAC8LTA4HCHRM4 | |
| SCHEMBL4296423 | 0.77 | KMT2A (0.48) | LTA4HCHRM4KMT2A | |
| SCHEMBL4431617 | 0.77 | KMT2A (0.48) | LTA4HCHRM4KMT2A | |
| SCHEMBL4048096 | 0.72 | LTA4H (0.53) | PKMGAALTA4H | |
| SCHEMBL18894019 | 0.72 | HDAC6 (0.62) | HDAC6HDAC1HDAC8PKMGAA | |
| SCHEMBL4281521 | 0.72 | HDAC6 (0.62) | HDAC6HDAC1HDAC8PKMGAA | |
| SCHEMBL26915184 | 0.72 | HDAC6 (0.62) | HDAC6HDAC1HDAC8PKMGAA | |
| SCHEMBL4286722 | 0.71 | PKM (0.52) | HDAC6HDAC1HDAC8PKMGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | HDAC6 903/4885HDAC1 67/4885HDAC8 168/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | HDAC6 903/4885HDAC1 67/4885HDAC8 168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.